Novavax Stock Slammed With Hefty Price-Target Cut

The analyst said the drugmaker's recent guidance cut may not have been low enough

Deputy Editor
Sep 22, 2022 at 9:42 AM
facebook twitter linkedin

The shares of Novavax, Inc. (NASDAQ:NVAX) are 4.9% lower this morning, last seen trading at $24.60, following a bear note from J.P. Morgan Securities. The firm downgraded NVAX to "underweight" from "neutral," and issued a hefty price-target cut to $27 from $132, saying that the drugmaker's recently lowered second-quarter revenue guidance might not have been enough as Covid-19 vaccine dynamics shift considerably in the U.S. and Europe.  

Coming into today, the brokerage bunch was split, leaving space for additional bear notes. Specifically, while three rated Novavax stock a "hold" or "sell," four analysts still recommended a "strong buy." What's more, the 12-month consensus target price of $105.83 is a massive 309.1% premium to last night's close, indicating a round of price-target cuts is long overdue. 

There's room for options traders to change their tune as well, as calls have been a popular choice in recent weeks. This is per NVAX's 10-day call/put volume ratio of 2.71 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits higher than 86% of readings from the past year. In other words, these bullish bets have been getting picked up at a much quicker-thank-usual clip of late.

Today's drop puts the security at its lowest level since April 2020, as it heads back toward its pre-pandemic levels. The equity finished yesterday's session nearly 92% below its Feb. 8. 2021 all-time high close of $319.93. The 10-day moving average began pressuring the shares lower in early August, and NVAX is now down more than 81.9% year-to-date.


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!